Drug Trial Radar · NCT00482209
Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation
Last checked: Nov 20, 2026Latest source record: Oct 12, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,220
Planned (sponsor's estimate)
Start
May 2007
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Gynuity Health ProjectsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This double-blind, randomized study will compare the efficacy and acceptability of mifepristone 200mg followed in 36-48 hours by 400mcg or 800mcg of buccal misoprostol (i.e., in the cheeks) for termination of pregnancy in women up to 63 days LMP.
Conditions
- Induced Abortion
Interventions
Mifepristone, misoprostolDrug
200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
mifepristone, misoprostolDrug
200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
Primary outcomes
What the sponsor says the trial is designed to measure.
- Need for surgical completion for ongoing viable pregnancies at follow up visit (Study day 12-15) or for incomplete abortion at extended follow up visit (Study day (19-22).Time frame: Study day 12-15 for ongoing viable pregnancies or Study day 19-22 for incomplete abortion at extended follow up visit
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Maternity House #2
Tbilisi, Georgia
Maternity House #4
Tbilisi, Georgia
Zhordania Institute of Human Reproduction
Tbilisi, Georgia
Hocmon Hospital
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.